← Back
FibroBiologics
FBLG · listed on Nasdaq · worth $6.88 million
$0.9685
−2.12% on Nov 4
Three insider buys in the last year, $89.6K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-20 in Mar 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what FBLG ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
5.2M shares
73% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders bought FibroBiologics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
General Counsel
Ruben A. Garcia
Bought $47.6K on Dec 11, 2025 — 140,000 shares at $0.3400, 100% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Chief Financial Officer
Jason Davis
Bought $29K on Mar 2 — 70,000 shares at $0.4139, 100% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of FibroBiologics, newest first.
Filed by someone who owns 5% or more and may try to influence how the company is run.Khoja Hamid7.5%Sep 17
All reports
Every insider trade and SEC report we hold for FibroBiologics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Dec 12, 2025BoughtRuben A. GarciaDec 12, 2025 · Traded Dec 11, 2025 · General Counsel+100%140,000 @ $0.3400$47.6K
Analysts, earnings and news
Analysts' price target
$12.50 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26−$0.66 a share+$0.27
Q1 '26−$1.33 a share+$0.02
Q4 '25−$0.60 a share+$1.40
Q3 '25−$2.60 a share−$0.30